⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14161812 | 1.00 | — | — | |
| SCHEMBL11967081 | 1.00 | — | — | |
| SCHEMBL3038803 | 1.00 | — | — | |
| SCHEMBL16995166 | 1.00 | — | — | |
| SCHEMBL43179 | 1.00 | — | — | |
| SCHEMBL13973916 | 1.00 | — | — | |
| SCHEMBL12127053 | 1.00 | — | — | |
| SCHEMBL1110014 | 0.97 | CA1 (0.62) | — | |
| SCHEMBL4847323 | 0.97 | CA1 (0.62) | — | |
| SCHEMBL17124636 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-11174264-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200231594-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
| WO-2019070742-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | SIDECAR THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-7695801-B2 | Optical systems and refractive index-matching compositions | AVAGO TECHNOLOGIES FIBER IP (SINGAPORE) PTE. LTD. (SG) | 2010-04-13 | — | — | US | disclosed |
| US-20050170146-A1 | Optical systems and refractive index-matching compositions | AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD. (SG) | 2005-08-04 | — | — | US | disclosed |
| US-6890619-B2 | Optical systems and refractive index-matching compositions | AGILENT TECHNOLOGIES, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1381593-A2 | (2-HYDROXY)ETHYL-THIOUREAS USEFUL AS MODULATORS OF ALPHA2B ADRENERGIC RECEPTORS | Allergan, Inc. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6534542-B2 | For alleviating chronic pain and allodynia and have no or only minimal cardivascular and/or sedatory activity | ALLERGEN SALES, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020161051-A1 | (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors | ALLERGAN SALES, INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2002068384-A2 | (2-HYDROXY)ETHYL-THIOUREAS USEFUL AS MODULATORS OF ALPHA2B ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2002-09-06 | — | — | WO | disclosed |